Results 61 to 70 of about 4,619,877 (335)

Surfaceome: a new era in the discovery of immune evasion mechanisms of circulating tumor cells

open access: yesMolecular Oncology, EarlyView.
In the era of immunotherapies, many patients either do not respond or eventually develop resistance. We propose to pave the way for proteomic analysis of surface‐expressed proteins called surfaceome, of circulating tumor cells. This approach seeks to identify immune evasion mechanisms and discover potential therapeutic targets. Circulating tumor cells (
Doryan Masmoudi   +3 more
wiley   +1 more source

Peripheral blood proteome biomarkers distinguish immunosuppressive features of cancer progression

open access: yesMolecular Oncology, EarlyView.
Immune status significantly influences cancer progression. This study used plasma proteomics to analyze benign 67NR and malignant 4T1 breast tumor models at early and late tumor stages. Immune‐related proteins–osteopontin (Spp1), lactotransferrin (Ltf), calreticulin (Calr) and peroxiredoxin 2 (Prdx2)–were associated with systemic myeloid‐derived ...
Yeon Ji Park   +6 more
wiley   +1 more source

Plasma lipidomic and metabolomic profiles in high‐grade glioma patients before and after 72‐h presurgery water‐only fasting

open access: yesMolecular Oncology, EarlyView.
Presurgery 72‐h fasting in GB patients leads to adaptations of plasma lipids and polar metabolites. Fasting reduces lysophosphatidylcholines and increases free fatty acids, shifts triglycerides toward long‐chain TGs and increases branched‐chain amino acids, alpha aminobutyric acid, and uric acid.
Iris Divé   +7 more
wiley   +1 more source

Targeting immunosuppression for cancer therapy [PDF]

open access: yesJournal of Clinical Investigation, 2013
Failing immunity has been acknowledged for its contribution to cancer development and progression. Recent clinical findings have provided payoffs for significant preclinical evaluation and refinement over the last 20 years, but many questions remain to be answered. In this issue of the JCI, Marabelle et al.
Cristina Ghirelli, Thorsten Hagemann
openaire   +3 more sources

CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in Lymphoma.

open access: yesHuman Gene Therapy, 2015
Chimeric antigen receptor (CAR) T-cells have shown remarkable results in patients with B-cell leukemia and lymphoma. However, while CAR T-cells have shown complete responses in a majority of patients with acute lymphoblastic leukemia (ALL), lymphomas are
G. Enblad, Hannah Karlsson, A. Loskog
semanticscholar   +1 more source

Early metastasis is characterized by Gr1+ cell dysregulation and is inhibited by immunomodulatory nanoparticles

open access: yesMolecular Oncology, EarlyView.
Breast cancer metastasis is associated with myeloid cell dysregulation and the lung‐specific accumulation of tumor‐supportive Gr1+ cells. Gr1+ cells support metastasis, in part, through a CHI3L1‐mediated mechanism, which can be targeted and inhibited with cargo‐free, polymeric nanoparticles.
Jeffrey A. Ma   +9 more
wiley   +1 more source

Financial Aspects of the Immunosuppressive Therapy

open access: yesMedical Archives, 2011
In this study the authors have analyzed the costs associated with the immunosuppressive therapy in patients who underwent organ transplantation in two countries: the United States of America and Bosnia and Herzegovina (i.e. the entity Federation B&H).The goal of this paper is to compare and contrast the costs of the immunosuppressive therapy in two ...
Ognjen Ridic   +6 more
openaire   +3 more sources

Systematic profiling of cancer‐fibroblast interactions reveals drug combinations in ovarian cancer

open access: yesMolecular Oncology, EarlyView.
Fibroblasts, cells in the tumor environment, support ovarian cancer cell growth and alter morphology and drug response. We used fibroblast and cancer cell co‐culture models to test 528 drugs and discovered new drugs for combination treatment. We showed that adding Vorinostat or Birinapant to standard chemotherapy may improve drug response, suggesting ...
Greta Gudoityte   +10 more
wiley   +1 more source

The clinical utility and safety of biomarker-guided immunosuppression withdrawal in liver transplantation: the LIFT prospective RCT

open access: yesEfficacy and Mechanism Evaluation
Background Long-term surviving liver transplant recipients can spontaneously develop operational tolerance, which allows them to completely discontinue their immunosuppression, but we lack validated tools to predict the likelihood of rejection following ...
Julien Vionnet   +22 more
doaj   +1 more source

FIRST EXPERIENCE OF APPLICATION OF ASSIST CIRCULATION DEVICE USING BIVENTRICULAR TYPE «EXCOR»

open access: yesВестник хирургии имени И.И. Грекова, 2018
The frequency of use of assist blood device as the «bridge» to the heart transplantation increased in last years. An assessment of results of first 7 implantations of assist circulation device using biventricular type «Excor» was made.
M. L. Gordeev   +12 more
doaj   +1 more source

Home - About - Disclaimer - Privacy